Jobs

Currently 4071 jobs

Candidates Login

CV Database

Let the jobs come to you!

Company Login

Site Newsletter

Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

PharmiWeb on Facebook

Advertising

Press Releases

submit a press release

65 Press Releases

1 2 3

Date	Title	Company
24 May 13	Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan	Astellas Pharma Inc., Published by Business Wire
23 May 13	ASTELLAS RECEIVES MARKETING AUTHORISATION FOR VESOMNITM FROM THE NETHERLANDS MEDICINES EVALUATION BOARD	ASTELLAS PHARMA EUROPE B.V, Published by red door communications
26 Apr 13	POSITIVE CHMP OPINION FOR XTANDI™ (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER	Astellas
21 Mar 13	Tokyo Institute of Technology and Astellas Launch Collaborative Research for New Anti-Dengue Virus Drugs for Neglected Tropical Diseases	Astellas Pharma Inc., Published by Business Wire
21 Mar 13	Nagasaki University and Astellas Launch Collaborative Research for Screening New Anti-Dengue Virus Drugs for Neglected Tropical Diseases	Astellas Pharma Inc., Published by Business Wire
14 Mar 13	European Commission approves new pre-treatment options for QUTENZAT (8% capsaicin patch) in peripheral neuropathic pain	Astellas Pharma Europe Ltd., Published by Pegasus
11 Mar 13	Non-inferiority Observed in Phase III Clinical Trial of Seasonal Flu Vaccine ASP7374	Astellas
22 Jan 13	Astellas' New Headquarters for the Americas Awarded LEED Gold Certification	ASTELLAS PHARMA INC., Published by PR Newswire
11 Dec 12	New phase II data demonstrates significant activity of quizartinib in relapsed or refractory acute myeloid leukaemia (AML) patients1,2	Astellas Pharma Inc., Published by Business Wire
19 Oct 12	MIRABEGRON RECEIVES POSITIVE CHMP OPINION FOR TREATMENT OF OVERACTIVE BLADDER SYMPTOMS	Astellas Pharma Ltd, Published by Red Door Communications
03 Oct 12	Astellas Pharma US Receives CEO Cancer Gold Standard Accreditation	Astellas
01 Oct 12	Medivation and Astellas Announce New Data From XTANDI® (enzalutamide) Pivotal Study	Astellas
01 Oct 12	AVEO and Astellas Announce New Data Presented at ESMO 2012 Congress Demonstrating the Safety and Tolerability Profile of Tivozanib in Patients with Advanced Kidney Cancer	AVEO Oncology & Astellas Pharma Inc., Published by Business Wire
30 Aug 12	Real-world efficacy of QUTENZA™ (8% capsaicin patch) confirms phase-III trial results, with improved patient quality of life and reduced use of healthcare resources	Astellas Pharma Europe Ltd
14 Aug 12	Astellas Pharma Europe Ltd. appoints Dr Susan Wood as Senior Director, Market Access	Astellas Pharma Europe Ltd
24 Jul 12	Astellas initiates head-to-head study comparing QUTENZA™ (8% capsaicin patch) and pregabalin in the treatment of peripheral neuropathic pain	Astellas Pharma Europe Ltd
10 Jul 12	DIFICLIR™ (fidaxomicin), the first new antibiotic for Clostridium difficile infection since the 1950s, accepted for restricted use within Scotland	Astellas
27 Jun 12	ASTELLAS ANNOUNCES SUBMISSION OF EUROPEAN MARKETING AUTHORISATION APPLICATION FOR ENZALUTAMIDE FOR THE TREATMENT OF MEN WITH ADVANCED PROSTATE CANCER POST-CHEMOTHERAPY	Astellas Pharma Inc, Published by Red Health
27 Jun 12	Astellas Announces Submission of European Marketing Authorisation Application for Enzalutamide for the Treatment of Men with Advanced Prostate Cancer Post-Chemotherapy	Astellas, Published by Business Wire
20 Jun 12	First new treatment for Clostridium difficile infection since the 1950’s, launched in the U.K today	Astellas
06 Jun 12	Tivozanib successfully demonstrates the longest reported progression-free survival in first line metastatic Renal Cell Carcinoma (RCC)	Astellas
17 May 12	Astellas & AVEO: Tivozanib Successfully Demonstrates the Longest Reported Progression-Free Survival in First Line Metastatic Renal Cell Carcinoma (RCC)1	Astellas, Published by Business Wire
20 Mar 12	Nerve pain patients in Wales gain access to first of a kind treatment which can provide lasting pain relief	Astellas Pharma Ltd
15 Mar 12	MDV3100 Extends Life by Nearly Five Months in Men with Advanced Prostate Cancer Post Chemotherapy 1	Astellas, Published by Business Wire
22 Feb 12	Astellas Hires Senior Vice President of New Global Medical Affairs Organization	Astellas
02 Feb 12	POSITIVE NEW PHASE III DATA FURTHER DEMONSTRATE EFFICACY AND TOLERABILITY OF MDV3100 IN MEN WITH PROSTATE CANCER POST CHEMOTHERAPY	Astellas
05 Jan 12	Tivozanib Successfully Demonstrates Progression-Free Survival Superiority Over Sorafenib in Patients with Advanced Renal Cell Cancer	Astellas Pharma Europe Ltd
03 Jan 12	AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial	AVEO Pharmaceuticals Inc. and Astellas Pharma Inc., Published by Business Wire
22 Dec 11	European Commission Grants Marketing Authorisation for Astellas Pharma Europe Ltd.’s DIFICLIR™ (fidaxomicin) for use in the EU	Astellas
11 Nov 11	Astellas Signs United Nations Global Compact	Astellas Pharma Inc., Published by Business Wire

1 2 3

subscribe in a reader

Advertising

Share | | |

Site Map
Privacy & Security
Cookies
Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.